Philip Doh, MD
Pain Medicine · Los Angeles, CANPI 1679511638
Payments from drug & device makers
Across 1,072 payments — averaging $27.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- IBSA Pharma Inc.$11K
- Amgen$4K
- Radius Health, Inc.$4K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
- Regeneron Healthcare Solutions, Inc.$1K
- Collegium Pharmaceutical, Inc.$1K
- plus $6K from 26 others
What the payments were for
- Consulting fees$6,90023%
- Travel & lodging$40%
- Food & beverage$22,67777%
- Education$70%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| IBSA Pharma Inc. | 235 | $10,743 |
| Amgen | 161 | $4,406 |
| Radius Health, Inc. | 180 | $4,358 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 106 | $1,781 |
| Regeneron Healthcare Solutions, Inc. | 19 | $1,009 |
| Collegium Pharmaceutical, Inc. | 58 | $1,006 |
| Redhill Biopharma Inc. | 42 | $828 |
| Almatica Pharma LLC | 46 | $813 |
| AbbVie(2 entities) | 16 | $729 |
| Pfizer | 41 | $676 |
| Biodelivery Sciences International, Inc. | 50 | $520 |
| Scilex Pharmaceuticals Inc. | 22 | $398 |
| Azurity Pharmaceuticals, Inc. | 15 | $321 |
| Arbor Pharmaceuticals, Inc. | 15 | $278 |
| Fidia Pharma USA Inc. | 12 | $243 |
| Biohaven Pharmaceuticals, Inc. | 5 | $183 |
| Pacira Therapeutics, Inc. | 6 | $171 |
| Daiichi Sankyo Inc. | 10 | $135 |
| Stryker | 2 | $134 |
| West Therapeutics Development, LLC | 7 | $126 |
| Avanir Pharmaceuticals, Inc. | 1 | $125 |
| Assertio Therapeutics, Inc. | 7 | $122 |
| Merck | 1 | $113 |
| Eisai Inc. | 2 | $70 |
| Exact Sciences | 3 | $65 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $55 |
| GRT US Holding, Inc. | 1 | $55 |
| Teva Pharmaceuticals USA, Inc. | 2 | $45 |
| Johnson & Johnson | 1 | $25 |
| Alvogen Inc | 1 | $24 |
| Paratek Pharmaceuticals, Inc. | 1 | $18 |
| Shionogi Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$29,588 in reported general payments places this provider in the 90th percentile of 840 pain medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TymlosAbaloparatide | 236 | $618,053 |
| LicartDiclofenac Epolamine | 384 | $579,839 |
| ProliaDenosumab | 127 | $216,444 |
| HorizantGabapentin Enacarbil | 116 | $128,635 |
| RelistorMethylnaltrexone Bromide | 21 | $93,708 |
| Evenity (2 Syringes)Romosozumab-Aqqg | 34 | $82,347 |
| Dupixent SyringeDupilumab | 18 | $67,322 |
| TrulicityDulaglutide | 65 | $62,294 |
| Teriparatide | 11 | $26,437 |
| BelbucaBuprenorphine Hcl | 23 | $15,633 |
| GraliseGabapentin | 13 | $12,281 |
| LyricaPregabalin | 14 | $12,091 |
| Diclofenac Epolamine | 24 | $11,404 |
| Diclofenac Sodium | 21 | $6,407 |
| ZtlidoLidocaine | 11 | $4,534 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Radius Health, Inc.Tymlos | $4,358 | $618,053236 claims |
| IBSA Pharma Inc.Licart | $10,743 | $579,839384 claims |
| AmgenProlia, Evenity (2 Syringes) | $4,406 | $298,791161 claims |
| Arbor Pharmaceuticals, Inc.Horizant | $278 | $128,635116 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor | $1,781 | $93,70821 claims |
| Alvogen IncTeriparatide | $24 | $26,43711 claims |
| Collegium Pharmaceutical, Inc.Belbuca | $1,006 | $15,63323 claims |
| Almatica Pharma LLCGralise | $813 | $12,28113 claims |
| PfizerLyrica | $676 | $12,09114 claims |
| Scilex Pharmaceuticals Inc.Ztlido | $398 | $4,53411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 840 pain medicine providers in California.
Other pain medicine in Los Angeles
- Francis FerranteLos Angeles$75K
- Eric GrigsbyNapa$3.2M
- Jason PopeSanta Rosa$2.8M
- Javid GhandehariSanta Monica$2.7M
- Alexander HerselThousand Oaks$2.1M
- Krishnan ChakravarthyTemecula$1.9M
- Kasra AmirdelfanWalnut Creek$1.7M
- Ramana NaiduLarkspur$1.6M
- Foead GeulaStudio City$1.3M
- Xiang QianRedwood City$941K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.